Ionis Pharmaceuticals Quarterly Balance Sheets Chart
Quarterly
|
Annual
Ionis Pharmaceuticals Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2019-03-31 | 2018-12-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-12-31 | 2013-09-30 | 2013-06-30 | 2013-03-31 | 2012-12-31 | 2012-09-30 | 2012-06-30 | 2012-03-31 | 2011-12-31 | 2011-09-30 | 2011-06-30 | 2011-03-31 | 2010-12-31 | 2010-09-30 | 2010-06-30 | 2010-03-31 | 2009-12-31 | 2009-09-30 | 2009-06-30 | 2009-03-31 | 2008-12-31 | 2008-09-30 | 2008-06-30 | 2008-03-31 | 2007-09-30 | 2007-06-30 | 2007-03-31 | 2006-12-31 | 2006-09-30 | 2006-06-30 | 2006-03-31 | 2005-12-31 | 2005-09-30 | 2005-06-30 | 2005-03-31 | 2004-09-30 | 2004-06-30 | 2004-03-31 | 2003-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| current assets: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cash and cash equivalents | 297,304,000 | 264,192,000 | 242,077,000 | 334,605,000 | 293,993,000 | 348,889,000 | 399,266,000 | 352,060,000 | 424,790,000 | 309,031,000 | 276,472,000 | 314,993,000 | 521,917,000 | 542,513,000 | 375,811,000 | 278,820,000 | 73,220,000 | 94,081,000 | 161,778,000 | 159,973,000 | 256,408,000 | 296,540,000 | 107,650,000 | 124,482,000 | 84,563,000 | 85,645,000 | 56,391,000 | 65,477,000 | 55,263,000 | 85,022,000 | 86,200,000 | 70,052,000 | 100,122,000 | 46,038,000 | 98,590,000 | 105,255,000 | 149,293,000 | 215,789,000 | 254,057,000 | 217,918,000 | 264,682,000 | 445,720,000 | 271,936,000 | 102,398,000 | 132,964,000 | 183,423,000 | 114,514,000 | 104,238,000 | 105,359,000 | 1,711,000 | 3,650 | 53,222,000 | 7,988,000 | 12,006,000 | 21,446,000 | 30,371,000 | 39,757,000 | |
| short-term investments | 1,992,676,000 | 1,880,960,000 | 2,055,579,000 | 2,148,671,000 | 1,784,693,000 | 1,857,327,000 | 1,931,935,000 | 1,883,522,000 | 1,960,598,000 | 2,037,750,000 | 1,710,397,000 | 1,666,670,000 | 1,499,910,000 | 1,509,880,000 | 1,877,943,000 | 1,805,252,000 | 518,766,000 | 496,754,000 | 469,515,000 | 496,788,000 | 414,490,000 | 294,212,000 | 264,261,000 | 249,964,000 | 259,010,000 | 250,384,000 | 277,553,000 | 278,187,000 | 309,500,000 | 310,162,000 | 340,622,000 | 402,301,000 | 397,782,000 | 475,990,000 | 420,529,000 | 469,057,000 | 458,547,000 | 421,722,000 | 398,179,000 | 273,080,000 | 247,341,000 | 91,249,000 | 66,479,000 | 43,593,000 | 69,769,000 | 102,131,000 | 78,819,000 | 22,633,000 | 32,581,000 | 76,850,000 | 90,739 | 48,435,000 | 51,592,000 | 70,778,000 | 104,119,000 | 116,973,000 | 141,116,000 | |
| contracts receivable | 52,580,000 | 39,707,000 | 92,188,000 | 17,928,000 | 27,259,000 | 5,140,000 | 97,778,000 | 142,359,000 | 27,956,000 | 13,914,000 | 25,538,000 | 6,645,000 | 6,751,000 | 26,122,000 | 10,452,000 | 12,759,000 | 26,313,000 | 41,941,000 | 9,823,000 | 11,102,000 | 12,645,000 | 2,024,000 | 1,172,000 | 522,000 | 3,476,000 | 1,558,000 | 1,379,000 | 6,921,000 | 1,858,000 | 5,674,000 | 591,000 | 1,242,000 | 1,341,000 | 5,040,000 | 1,904,000 | 10,899,000 | 586,000 | 783,000 | 2,351,000 | 4,121,000 | 5,021,000 | 6,399,000 | 4,358,000 | 9,237,000 | 2,296,000 | 2,057,000 | 2,395,000 | 2,959,000 | 2,618,000 | 3,503,000 | 3,918 | 4,209,000 | 4,456,000 | 2,911,000 | 5,464,000 | 9,593,000 | 5,774,000 | |
| inventories | 8,481,000 | 11,502,000 | 12,512,000 | 28,452,000 | 28,723,000 | 30,259,000 | 28,425,000 | 25,634,000 | 25,538,000 | 22,200,000 | 22,033,000 | 20,645,000 | 19,811,000 | 24,032,000 | 11,057,000 | 8,582,000 | 7,085,000 | 7,776,000 | 7,537,000 | 8,033,000 | 7,385,000 | 8,309,000 | 5,809,000 | 6,121,000 | 6,737,000 | 7,108,000 | 4,873,000 | 4,139,000 | 2,915,000 | 2,249,000 | 2,606,000 | 2,484,000 | 1,996,000 | 2,794,000 | 2,601,000 | 2,768,000 | 2,817,000 | 2,779,000 | 2,591,000 | 2,718,000 | 5,511,000 | 4,699,000 | 3,700,000 | 1,930,000 | 1,510,000 | |||||||||||||
| other current assets | 226,109,000 | 222,571,000 | 217,934,000 | 184,194,000 | 194,715,000 | 174,060,000 | 184,449,000 | 181,075,000 | 177,872,000 | 159,724,000 | 168,254,000 | 143,173,000 | 142,759,000 | 150,577,000 | 98,686,000 | 102,473,000 | 8,353,000 | 8,567,000 | 9,814,000 | 7,518,000 | 7,372,000 | 5,786,000 | 8,074,000 | 8,727,000 | 7,800,000 | 5,724,000 | 7,417,000 | 5,415,000 | 7,553,000 | 7,613,000 | 7,376,000 | 7,058,000 | 6,309,000 | 7,023,000 | 6,791,000 | 8,147,000 | 8,004,000 | 6,439,000 | 6,514,000 | 5,085,000 | 6,988,000 | 7,113,000 | 6,378,000 | 4,229,000 | 4,238,000 | 7,363,000 | 9,614,000 | 6,461,000 | 6,830,000 | 7,918,000 | 6,600 | 7,459,000 | 7,260,000 | 8,574,000 | 8,236,000 | 9,281,000 | 7,686,000 | |
| total current assets | 2,577,150,000 | 2,418,932,000 | 2,620,290,000 | 2,713,850,000 | 2,329,383,000 | 2,415,675,000 | 2,641,853,000 | 2,584,650,000 | 2,616,754,000 | 2,542,619,000 | 2,202,694,000 | 2,152,126,000 | 2,191,148,000 | 2,253,124,000 | 2,373,949,000 | 2,207,886,000 | 681,163,000 | 705,797,000 | 722,053,000 | 735,510,000 | 763,304,000 | 669,061,000 | 431,829,000 | 423,438,000 | 361,586,000 | 350,419,000 | 347,613,000 | 360,139,000 | 377,089,000 | 410,720,000 | 437,395,000 | 483,137,000 | 507,550,000 | 536,885,000 | 530,415,000 | 596,126,000 | 619,247,000 | 647,512,000 | 663,692,000 | 518,384,000 | 529,543,000 | 555,180,000 | 352,851,000 | 161,387,000 | 210,777,000 | 296,067,000 | 206,203,000 | 136,923,000 | 148,274,000 | 90,731,000 | 105,858 | 114,242,000 | 72,367,000 | 96,991,000 | 159,355,000 | 182,292,000 | 208,881,000 | |
| property, plant and equipment | 111,951,000 | 102,925,000 | 94,251,000 | 82,502,000 | 75,902,000 | 72,795,000 | 71,043,000 | 70,928,000 | 91,634,000 | 85,158,000 | 74,294,000 | 180,806,000 | 177,015,000 | 177,724,000 | 133,519,000 | 132,160,000 | 88,068,000 | 86,321,000 | 86,641,000 | 86,198,000 | 87,273,000 | 88,312,000 | 89,694,000 | 91,084,000 | 92,598,000 | 94,008,000 | 95,132,000 | 96,615,000 | 98,019,000 | 88,010,000 | 37,680,000 | 35,703,000 | 35,549,000 | 36,071,000 | 36,171,000 | 27,338,000 | 26,911,000 | 26,636,000 | 24,183,000 | 17,371,000 | 14,019,000 | 10,494,000 | 8,274,000 | 6,583,000 | 6,890,000 | 7,042,000 | 7,157,000 | 7,227,000 | 7,563,000 | 8,208,000 | 9,130 | 10,181,000 | 22,837,000 | 26,665,000 | 30,857,000 | 32,172,000 | 32,721,000 | |
| right-of-use assets | 163,933,000 | 159,269,000 | 161,856,000 | 164,424,000 | 166,939,000 | 169,431,000 | 171,896,000 | 174,310,000 | 176,718,000 | 179,148,000 | 181,544,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| deposits and other assets | 132,099,000 | 131,822,000 | 127,278,000 | 120,323,000 | 118,904,000 | 106,027,000 | 105,280,000 | 104,083,000 | 86,025,000 | 78,296,000 | 75,344,000 | 59,434,000 | 58,916,000 | 58,949,000 | 25,954,000 | 12,910,000 | 4,533,000 | 5,299,000 | 5,438,000 | 5,359,000 | 5,481,000 | 5,601,000 | 5,824,000 | 5,939,000 | 6,126,000 | 2,460,000 | 2,570,000 | 2,845,000 | 3,121,000 | 3,269,000 | 3,398,000 | 3,528,000 | 3,658,000 | 3,789,000 | 3,211,000 | 3,269,000 | 3,441,000 | 3,590,000 | 3,739,000 | 5,274,000 | 5,557,000 | 7,229,000 | 2,854,000 | 2,806,000 | 2,809,000 | 2,797,000 | 4,276,000 | 2,433,000 | 2,667,000 | 2,883,000 | 3,201 | 3,359,000 | 3,220,000 | 3,422,000 | 8,052,000 | 8,253,000 | 8,411,000 | |
| total assets | 2,985,133,000 | 2,812,948,000 | 3,003,675,000 | 3,081,099,000 | 2,691,128,000 | 2,763,928,000 | 2,990,072,000 | 2,933,971,000 | 2,971,131,000 | 2,885,221,000 | 2,533,876,000 | 2,421,971,000 | 2,456,133,000 | 2,519,092,000 | 2,835,889,000 | 2,667,784,000 | 793,803,000 | 817,777,000 | 834,616,000 | 847,156,000 | 881,916,000 | 788,651,000 | 552,961,000 | 545,686,000 | 485,681,000 | 472,394,000 | 470,807,000 | 484,894,000 | 505,785,000 | 529,572,000 | 505,942,000 | 550,477,000 | 575,858,000 | 606,351,000 | 599,723,000 | 657,184,000 | 680,578,000 | 709,161,000 | 724,506,000 | 574,150,000 | 584,692,000 | 609,399,000 | 405,424,000 | 213,003,000 | 263,255,000 | 349,904,000 | 255,907,000 | 187,768,000 | 201,919,000 | 150,637,000 | 166,373 | 177,382,000 | 146,526,000 | 175,648,000 | 255,271,000 | 279,962,000 | 312,726,000 | |
| liabilities and stockholders’ equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| current liabilities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| accounts payable | 22,800,000 | 17,456,000 | 42,964,000 | 9,052,000 | 9,243,000 | 13,082,000 | 26,027,000 | 5,615,000 | 24,021,000 | 10,499,000 | 17,921,000 | 20,545,000 | 10,351,000 | 16,125,000 | 13,332,000 | 28,660,000 | 15,627,000 | 13,453,000 | 9,869,000 | 11,009,000 | 8,781,000 | 9,461,000 | 5,385,000 | 10,239,000 | 5,256,000 | 6,194,000 | 5,344,000 | 8,300,000 | 6,653,000 | 3,071,000 | 4,652,000 | 6,523,000 | 3,392,000 | 5,355,000 | 4,843,000 | 4,696,000 | 5,554,000 | 6,659,000 | 7,445,000 | 5,710,000 | 6,885,000 | 5,716,000 | 5,633,000 | 4,507,000 | 4,161,000 | 3,274,000 | 4,288,000 | 3,003,000 | 3,267,000 | 2,483,000 | 2,095 | 2,833,000 | 2,297,000 | 2,240,000 | 2,818,000 | 3,416,000 | 3,349,000 | |
| accrued compensation | 46,564,000 | 26,575,000 | 69,614,000 | 40,558,000 | 35,018,000 | 21,537,000 | 67,727,000 | 33,781,000 | 29,322,000 | 18,160,000 | 49,178,000 | 30,410,000 | 24,985,000 | 16,525,000 | 16,264,000 | 29,268,000 | 7,164,000 | 6,430,000 | 4,328,000 | 12,168,000 | 6,653,000 | 7,031,000 | 3,818,000 | 7,878,000 | 5,836,000 | 4,939,000 | 3,502,000 | 9,183,000 | 5,233,000 | 4,406,000 | 3,076,000 | 6,831,000 | 4,833,000 | 4,312,000 | 2,971,000 | 7,135,000 | 4,763,000 | 4,460,000 | 3,181,000 | 6,835,000 | 3,956,000 | 3,631,000 | 2,449,000 | 4,920,000 | 2,379,000 | 2,017,000 | 6,222,000 | 1,332,000 | 1,628,000 | 1,517,000 | 3,706 | 1,306,000 | 1,736,000 | 1,811,000 | 3,819,000 | 3,033,000 | 2,058,000 | |
| accrued liabilities | 98,957,000 | 102,735,000 | 108,438,000 | 124,396,000 | 114,330,000 | 106,048,000 | 147,894,000 | 118,968,000 | 104,745,000 | 112,702,000 | 140,101,000 | 128,002,000 | 134,336,000 | 99,256,000 | 45,130,000 | 48,361,000 | 29,140,000 | 25,166,000 | 27,903,000 | 22,092,000 | 22,283,000 | 16,514,000 | 17,758,000 | 15,401,000 | 11,900,000 | 15,619,000 | 15,600,000 | 18,655,000 | 15,071,000 | 10,873,000 | 8,134,000 | 12,389,000 | 10,285,000 | 13,302,000 | 9,371,000 | 12,339,000 | 7,491,000 | 8,422,000 | 7,750,000 | 9,556,000 | 5,979,000 | 7,441,000 | 5,301,000 | 5,278,000 | 5,094,000 | 7,300,000 | 6,071,000 | 6,846,000 | 6,932,000 | 7,871,000 | 8,643 | 10,042,000 | 7,988,000 | 11,902,000 | 10,430,000 | 7,900,000 | 8,049,000 | |
| income taxes payable | 81,000 | 126,000 | 34,000 | 41,000 | 284,000 | 2,210,000 | 2,151,000 | 31,070,000 | 24,732,000 | 17,286,000 | 6,249,000 | 16,000 | 14,000 | 901,000 | 18,401,000 | 7,323,000 | 15,864,000 | 23,233,000 | 29,627,000 | |||||||||||||||||||||||||||||||||||||||
| 0 percent convertible senior notes | 630,118,000 | 629,326,000 | 628,535,000 | 627,745,000 | 626,955,000 | 626,167,000 | 625,380,000 | 624,594,000 | 623,809,000 | 623,025,000 | 622,242,000 | 621,460,000 | 620,678,000 | 619,898,000 | ||||||||||||||||||||||||||||||||||||||||||||
| current portion of deferred contract revenue | 75,910,000 | 81,097,000 | 78,989,000 | 76,018,000 | 94,066,000 | 130,406,000 | 151,128,000 | 204,824,000 | 96,252,000 | 92,335,000 | 90,577,000 | 99,511,000 | 93,393,000 | 91,437,000 | 144,846,000 | 160,256,000 | 51,727,000 | 51,560,000 | 54,428,000 | 48,135,000 | 55,977,000 | 40,409,000 | 35,244,000 | 35,925,000 | 23,427,000 | 22,998,000 | 34,320,000 | 36,584,000 | 52,428,000 | 68,719,000 | 73,392,000 | 74,502,000 | 77,268,000 | 77,268,000 | 70,890,000 | 75,681,000 | 76,941,000 | 82,092,000 | 85,581,000 | 92,662,000 | 99,794,000 | 101,507,000 | 57,951,000 | 7,804,000 | 6,070,000 | 1,043,000 | 1,044,000 | 571,000 | 712,000 | 1,111,000 | 1,514 | 1,410,000 | 4,926,000 | 10,435,000 | 15,801,000 | 17,523,000 | 15,832,000 | |
| other current liabilities | 22,806,000 | 22,304,000 | 9,279,000 | 10,034,000 | 8,799,000 | 9,988,000 | 8,831,000 | 9,952,000 | 8,903,000 | 8,239,000 | 7,535,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| total current liabilities | 897,236,000 | 250,293,000 | 309,318,000 | 304,566,000 | 306,162,000 | 327,648,000 | 448,090,000 | 404,210,000 | 287,975,000 | 259,221,000 | 311,561,000 | 283,454,000 | 267,811,000 | 228,450,000 | 252,473,000 | 280,294,000 | 107,325,000 | 100,816,000 | 100,836,000 | 97,812,000 | 103,278,000 | 86,995,000 | 70,295,000 | 74,322,000 | 51,601,000 | 55,063,000 | 61,707,000 | 76,112,000 | 83,542,000 | 91,980,000 | 94,399,000 | 105,890,000 | 100,916,000 | 105,214,000 | 92,095,000 | 111,444,000 | 114,719,000 | 127,861,000 | 136,460,000 | 124,698,000 | 117,683,000 | 127,111,000 | 80,260,000 | 29,966,000 | 25,178,000 | 101,941,000 | 25,139,000 | 19,436,000 | 20,281,000 | 20,845,000 | 23,793 | 23,905,000 | 26,053,000 | 36,062,000 | 42,897,000 | 42,132,000 | 39,643,000 | |
| long-term deferred contract revenue | 125,095,000 | 140,678,000 | 156,504,000 | 173,776,000 | 188,701,000 | 215,088,000 | 241,184,000 | 249,272,000 | 254,398,000 | 272,973,000 | 287,768,000 | 294,656,000 | 315,196,000 | 333,138,000 | 542,416,000 | 567,359,000 | 110,614,000 | 120,387,000 | 130,755,000 | 142,790,000 | 151,006,000 | 75,184,000 | 58,816,000 | 66,656,000 | 36,961,000 | 31,715,000 | 35,469,000 | 17,474,000 | 19,415,000 | 21,356,000 | 32,065,000 | 50,413,000 | 70,900,000 | 90,164,000 | 81,457,000 | 107,097,000 | 125,237,000 | 143,376,000 | 154,293,000 | 172,766,000 | 191,279,000 | 214,202,000 | 84,798,000 | 8,131,000 | 9,310,000 | 143,000 | 44,000 | |||||||||||
| 1.75 percent convertible senior notes | 566,420,000 | 565,721,000 | 565,026,000 | 564,335,000 | 563,647,000 | 562,964,000 | 562,285,000 | 561,609,000 | 560,937,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
| liability related to sale of future royalties | 541,205,000 | 536,141,000 | 542,212,000 | 538,102,000 | 533,754,000 | 525,072,000 | 513,736,000 | 512,700,000 | 510,174,000 | 505,081,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| long-term lease liabilities | 164,379,000 | 159,392,000 | 161,805,000 | 168,372,000 | 166,438,000 | 168,674,000 | 170,875,000 | 173,038,000 | 175,020,000 | 177,000,000 | 178,941,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| long-term obligations | 59,074,000 | 55,671,000 | 51,924,000 | 41,735,000 | 41,773,000 | 41,800,000 | 41,836,000 | 48,801,000 | 16,436,000 | 7,487,000 | 7,126,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| total liabilities | 2,353,409,000 | 2,337,222,000 | 2,415,324,000 | 2,418,631,000 | 2,427,430,000 | 2,467,413,000 | 2,603,386,000 | 2,618,511,000 | 2,542,830,000 | 2,398,651,000 | 1,960,989,000 | 1,827,610,000 | 1,831,407,000 | 1,809,518,000 | 1,448,469,000 | 1,480,624,000 | 449,031,000 | 450,917,000 | 460,514,000 | 468,766,000 | 480,470,000 | 387,570,000 | 351,870,000 | 362,920,000 | 315,404,000 | 318,080,000 | 319,935,000 | 313,460,000 | 318,960,000 | 317,355,000 | 278,239,000 | 305,935,000 | 322,149,000 | 344,122,000 | 315,286,000 | 355,119,000 | 375,753,000 | 403,344,000 | 421,836,000 | 469,902,000 | 476,940,000 | 509,228,000 | 327,949,000 | 202,819,000 | 201,041,000 | 270,473,000 | 158,005,000 | 154,172,000 | 156,454,000 | 173,342,000 | ||||||||
| stockholders’ equity: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| common stock | 159,000 | 159,000 | 158,000 | 158,000 | 146,000 | 146,000 | 144,000 | 143,000 | 143,000 | 143,000 | 142,000 | 142,000 | 142,000 | 142,000 | 140,000 | 138,000 | 118,000 | 118,000 | 118,000 | 116,000 | 116,000 | 114,000 | 103,000 | 102,000 | 102,000 | 100,000 | 100,000 | 100,000 | 100,000 | 100,000 | 100,000 | 99,000 | 99,000 | 99,000 | 99,000 | 99,000 | 98,000 | 98,000 | 98,000 | 97,000 | 96,000 | 95,000 | 93,000 | 87,000 | 82,000 | 82,000 | 82,000 | 74,000 | 73,000 | 73,000 | 72 | 72,000 | 58,000 | 58,000 | 57,000 | 57,000 | 56,000 | |
| additional paid-in capital | 2,932,747,000 | 2,901,262,000 | 2,868,812,000 | 2,831,942,000 | 2,303,369,000 | 2,270,047,000 | 2,215,098,000 | 2,148,002,000 | 2,118,309,000 | 2,089,358,000 | 2,059,850,000 | 2,034,554,000 | 2,008,794,000 | 1,983,078,000 | 2,117,969,000 | 2,047,250,000 | 1,365,407,000 | 1,352,994,000 | 1,343,874,000 | 1,324,804,000 | 1,315,643,000 | 1,292,745,000 | 1,091,842,000 | 1,077,150,000 | 1,073,658,000 | 1,019,936,000 | 1,016,497,000 | 1,013,592,000 | 1,009,330,000 | 1,006,288,000 | 1,003,595,000 | 1,000,181,000 | 995,149,000 | 991,436,000 | 988,053,000 | 985,620,000 | 978,411,000 | 972,697,000 | 967,648,000 | 905,721,000 | 900,303,000 | 890,435,000 | 884,434,000 | 820,422,000 | 887,579,000 | 884,506,000 | 880,954,000 | 802,063,000 | 795,026,000 | 774,366,000 | 770,263 | 764,555,000 | 623,385,000 | 623,361,000 | 622,395,000 | 622,106,000 | 610,517,000 | |
| accumulated other comprehensive income | 16,894,000 | 24,719,000 | 29,000,000 | 21,080,000 | 29,021,000 | 12,480,000 | 399,000 | 689,000 | 949,000 | 1,162,000 | 941,000 | 1,379,000 | 2,153,000 | 3,678,000 | 2,324,000 | 473,000 | 982,000 | 2,730,000 | 2,123,000 | 511,000 | 418,000 | 2,081,000 | 4,278,000 | 2,045,000 | 2,114,000 | 5,739,000 | 3,178 | 2,349,000 | 141,000 | 544,000 | 956,000 | 4,747,000 | ||||||||||||||||||||||||||
| accumulated deficit | -2,396,746,000 | -2,249,808,000 | -2,145,459,000 | -2,004,979,000 | -1,938,714,000 | -1,795,911,000 | -1,786,648,000 | -1,639,238,000 | -1,553,948,000 | -1,429,625,000 | -1,377,195,000 | -1,330,203,000 | -1,225,068,000 | -882,850,000 | -967,293,000 | -1,037,647,000 | -1,010,971,000 | -998,890,000 | -840,795,000 | |||||||||||||||||||||||||||||||||||||||
| total stockholders' equity | 631,724,000 | 366,860,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| total liabilities and stockholders’ equity | 2,985,133,000 | 2,812,948,000 | 3,003,675,000 | 3,081,099,000 | 2,691,128,000 | 2,763,928,000 | 2,990,072,000 | 2,933,971,000 | 2,971,131,000 | 2,885,221,000 | 2,533,876,000 | 2,421,971,000 | 2,456,133,000 | 2,519,092,000 | 2,835,889,000 | 2,667,784,000 | 793,803,000 | 834,616,000 | 847,156,000 | 881,916,000 | 788,651,000 | 552,961,000 | 545,686,000 | 485,681,000 | 472,394,000 | 470,807,000 | 484,894,000 | 505,785,000 | 529,572,000 | 505,942,000 | 550,477,000 | 575,858,000 | 606,351,000 | 599,723,000 | 657,184,000 | 680,578,000 | 709,161,000 | 724,506,000 | 150,637,000 | 166,373 | 177,382,000 | 255,271,000 | 279,962,000 | 312,726,000 | ||||||||||||||
| accumulated other comprehensive loss | -28,949,000 | -30,811,000 | -24,173,000 | -34,838,000 | -34,964,000 | -32,645,000 | -46,037,000 | -50,913,000 | -48,983,000 | -57,480,000 | -63,140,000 | -54,007,000 | -48,578,000 | -27,608,000 | -32,016,000 | |||||||||||||||||||||||||||||||||||||||||||
| total stockholders’ equity | 475,726,000 | 588,351,000 | 662,468,000 | 263,698,000 | 296,515,000 | 386,686,000 | 315,460,000 | 428,301,000 | 486,570,000 | 572,887,000 | 594,361,000 | 624,726,000 | 709,574,000 | 1,387,420,000 | 1,187,160,000 | 344,772,000 | 374,102,000 | 378,390,000 | 401,446,000 | 401,081,000 | 201,091,000 | 182,766,000 | 170,277,000 | 154,314,000 | 150,872,000 | 171,434,000 | 186,825,000 | 212,217,000 | 227,703,000 | 244,542,000 | 253,709,000 | 262,229,000 | 284,437,000 | 302,065,000 | 304,825,000 | 305,817,000 | 302,670,000 | 67,092,000 | 68,078,000 | 59,023,000 | 54,621,000 | 232,000 | 47,284,000 | 56,898,000 | 68,563,000 | 1,577,000 | 6,713,000 | 2,665 | 4,040,000 | 11,611,000 | 47,554,000 | |||||||
| 0.125 percent convertible senior notes | 44,467,000 | 44,422,000 | 44,377,000 | 44,332,000 | 44,287,000 | 114,081,000 | 545,053,000 | 544,504,000 | 543,955,000 | 543,407,000 | 542,860,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| long-term mortgage debt | 8,811,000 | 8,847,000 | 58,978,000 | 59,222,000 | 59,462,000 | 59,860,000 | 59,842,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| patents | 29,605,000 | 29,054,000 | 29,295,000 | 25,220,000 | 24,032,000 | 16,879,000 | 16,729,000 | 16,383,000 | 15,517,000 | 20,810,000 | 20,149,000 | 19,604,000 | 18,646,000 | 18,180,000 | 17,701,000 | 17,071,000 | 16,259,000 | 16,994,000 | 16,444,000 | 15,773,000 | 15,821,000 | 16,208,000 | 16,152,000 | 15,919,000 | 15,909,000 | 15,851,000 | 15,709,000 | 16,616,000 | 16,260,000 | 18,126,000 | 18,538,000 | 18,390,000 | 17,605,000 | 17,376,000 | 17,037,000 | 16,836,000 | 17,042,000 | 18,688,000 | 18,875,000 | 18,773 | 20,148,000 | 19,869,000 | 19,745,000 | 25,981,000 | 24,691,000 | 23,556,000 | ||||||||||||
| current portion of long-term obligations | 4,970,000 | 4,732,000 | 4,206,000 | 14,500,000 | 13,749,000 | 3,667,000 | 4,207,000 | 4,308,000 | 4,408,000 | 4,649,000 | 4,853,000 | 4,508,000 | 4,879,000 | 5,182,000 | 5,313,000 | 2,941,000 | 3,390,000 | 4,157,000 | 4,911,000 | 5,145,000 | 5,645,000 | 5,138,000 | 4,977,000 | 4,020,000 | 4,270,000 | 4,106,000 | 2,995,000 | 2,876,000 | 2,065,000 | 3,669,000 | 5,471,000 | 7,457,000 | 7,474,000 | 7,482,000 | 7,514,000 | 7,684,000 | 7,742,000 | 7,863,000 | 7,835 | 8,314,000 | 9,106,000 | 9,674,000 | 10,029,000 | 10,260,000 | 10,355,000 | |||||||||||||
| long-term obligations, less current portion | 25,107,000 | 25,093,000 | 25,710,000 | 16,305,000 | 4,914,000 | 4,039,000 | 4,510,000 | 5,523,000 | 6,542,000 | 6,384,000 | 7,382,000 | 6,498,000 | 7,402,000 | 8,404,000 | 9,503,000 | 3,603,000 | 4,125,000 | 4,724,000 | 5,465,000 | 4,938,000 | 5,720,000 | 4,304,000 | 5,620,000 | 4,474,000 | 11,478,000 | 12,532,000 | 10,643,000 | 11,370,000 | 9,938,000 | 5,478,000 | 5,415,000 | 391,000 | 2,222,000 | 4,053,000 | 5,889,000 | 7,822,000 | 9,736,000 | 11,173,000 | 12,942,000 | 14,915 | 16,845,000 | 119,432,000 | 118,358,000 | 104,369,000 | 99,033,000 | 94,558,000 | ||||||||||||
| long-term deferred tax assets | 277,247,000 | 290,796,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 1 percent convertible senior notes | 577,415,000 | 568,215,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| total ionis stockholders’ equity | 1,207,651,000 | 1,048,079,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| noncontrolling interest in akcea therapeutics, inc. | 179,769,000 | 139,081,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| investment in regulus therapeutics inc. | 47,426,000 | 56,678,000 | 63,586,000 | 52,096,000 | 65,004,000 | 62,190,000 | 44,863,000 | 33,622,000 | 5,563,000 | 5,563,000 | 5,400,000 | 4,424,000 | 3,145,000 | 2,759,000 | 1,726,000 | 870,000 | 5,000,000 | 4,070,000 | 127,000 | |||||||||||||||||||||||||||||||||||||||
| licenses | 3,160,000 | 3,631,000 | 4,101,000 | 4,572,000 | 5,048,000 | 5,528,000 | 6,010,000 | 6,579,000 | 7,191,000 | 7,806,000 | 8,421,000 | 9,036,000 | 10,562,000 | 11,129,000 | 11,696,000 | 12,288,000 | 12,893,000 | 13,454,000 | 14,007,000 | 14,542,000 | 15,128,000 | 15,714,000 | 16,276,000 | 16,861,000 | 17,447,000 | 17,958,000 | 18,516,000 | 19,684,000 | 20,267,000 | 20,851,000 | 21,435,000 | 22,018,000 | 22,602,000 | 23,186,000 | 23,770 | 24,353,000 | 24,937,000 | 25,521,000 | 26,619,000 | 27,200,000 | 27,782,000 | |||||||||||||||||
| 2¾ percent convertible senior notes | 155,437,000 | 152,005,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| long-term financing liability for leased facility | 71,616,000 | 71,504,000 | 71,395,000 | 71,288,000 | 71,097,000 | 70,910,000 | 70,728,000 | 70,550,000 | 70,375,000 | 70,205,000 | 70,039,000 | 69,877,000 | 68,895,000 | 58,722,000 | ||||||||||||||||||||||||||||||||||||||||||||
| liabilities and stockholders' equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 23/4 percent convertible senior notes | 153,700,000 | 148,705,000 | 147,099,000 | 145,533,000 | 142,500,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| stockholders' equity: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| total liabilities and stockholders' equity | 817,777,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 23¤4 percent convertible senior notes | 150,334,000 | 143,990,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| accrued income taxes | 4,935,000 | 8,727,000 | 3,582,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| accumulated other comprehensive gain | 26,986,000 | 17,784,000 | 846,000 | 968,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 25¤8 percent convertible subordinated notes | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 25/8 percent convertible subordinated notes | 146,031,000 | 143,717,000 | 141,448,000 | 139,239,000 | 134,964,000 | 132,895,000 | 125,100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| 25/8% convertible subordinated notes | 137,073,000 | 130,882,000 | 128,907,000 | 126,986,000 | 123,265,000 | 121,464,000 | 119,713,000 | 162,500,000 | 162,500,000 | 162,500,000 | 162,500,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| long-term financing obligation | 10,147,000 | 10,147,000 | 10,147,000 | 10,147,000 | 10,147,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| total isis pharmaceuticals, inc. stockholders’ equity | 244,542,000 | 253,709,000 | 262,229,000 | 284,437,000 | 291,722,000 | 292,995,000 | 292,851,000 | 288,846,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| noncontrolling interest in regulus therapeutics inc. | 10,343,000 | 11,830,000 | 12,966,000 | 13,824,000 | 4,737,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| assets from discontinued operations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| liabilities from discontinued operations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| noncontrolling interest in ibis biosciences, inc. — discontinued operations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| assets held for sale | 15,462,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| liabilities held for sale | 7,870,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| noncontrolling interest in ibis biosciences, inc. — held for sale. | 32,419,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| total liabilities, noncontrolling interest and stockholders’ equity | 574,150,000 | 584,692,000 | 609,399,000 | 405,424,000 | 213,003,000 | 263,255,000 | 349,904,000 | 255,907,000 | 187,768,000 | 201,919,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| derivative instrument related to abbott’s call option | 1,069,000 | 5,147,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| noncontrolling interest in regulus therapeutics llc | 6,315,000 | 7,523,000 | 8,488,000 | 9,952,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| noncontrolling interest in ibis biosciences, inc. | 33,359,000 | 33,625,000 | 14,366,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| debt issuance costs | 4,539,000 | 4,938,000 | 5,136,000 | 6,110,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| derivative instruments related to abbott’s subscription right and call option | 3,455,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 25¤8% convertible subordinated notes | 162,500,000 | 162,500,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 5 1/2% convertible subordinated notes | 125,000,000 | 125,000,000 | 125,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2 5/8% convertible subordinated notes | 162,500,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| noncontrolling interest in symphony genisis, inc. | 29,339,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 51/2% convertible subordinated notes | 125,000 | 125,000,000 | 125,000,000 | 125,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| noncontrolling interest in symphony genisis, inc | 14,930,000 | 22,533,000 | 32,019,000 | 38,752,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| inventory | 1,093,000 | 861,000 | 632,000 | 886,000 | 749,000 | 951 | 917,000 | 1,071,000 | 2,722,000 | 20,090,000 | 16,074,000 | 14,548,000 | ||||||||||||||||||||||||||||||||||||||||||||||
| current portion of 51¤2% convertible subordinated notes | 80,825,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 51¤2% convertible subordinated notes | 125,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| long-term investments | 2,125,000 | 2,125,000 | 6,754,000 | 5,099,000 | 3,296,000 | 3,304,000 | 4,407,000 | 5,354,000 | 11,375,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
| stockholders’ equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| investments in corporate securities | 5,641 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| long-term deferred contract revenue, less current portion | 92,000 | 230,000 | 378,000 | 644,000 | 2,186,000 | 5,971,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| deferred compensation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| common stock warrants | 7,500,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| liabilities and stockholders’ deficit | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| stockholders’ deficit: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| total stockholders’ deficit | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| total liabilities and stockholders’ deficit | 146,526,000 | 175,648,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| revenue: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| research and development revenue under collaborative agreements | 10,438,000 | 7,135,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| licensing and royalty revenue | 154,000 | 307,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| total revenue | 10,592,000 | 7,442,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| operating expenses: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| research and development | 20,950,000 | 22,361,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| general and administrative | 1,910,000 | 2,137,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| compensation benefit related to stock options | 5,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| restructuring activities | 650,000 | 7,084,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| total operating expenses | 23,515,000 | 30,949,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income from operations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| other income | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| investment income | 349,000 | 504,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| interest expense | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| accretion of dividends on preferred stock | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income applicable to common stock | -19,659,000 | -29,658,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic and diluted net income per share | -340 | -520 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| shares used in computing basic and diluted net income per share | 57,524,000 | 57,521,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 5 ½% convertible subordinated notes | 125,000,000 | 125,000,000 | 125,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| series b convertible exchangeable 5% preferred stock, 0.001 par value; 4,605 shares authorized, no shares issued or outstanding at september 30, 2004; 16,620 shares authorized, 12,015 shares issued and outstanding at december 31, 2003 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| accretion of series b preferred stock dividends | 2,741,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| series b convertible exchangeable 5% preferred stock, 0.001 par value; 4,605 shares authorized, no shares issued or outstanding at june 30, 2004; 16,620 shares authorized, 12,015 shares issued and outstanding at december 31, 2003 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| series b convertible exchangeable 5% preferred stock, .001 par value; 16,620 shares authorized, 12,015 shares issued and outstanding at march 31, 2004 and december 31, 2003 | 12,015,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| results of operations: |
We provide you with 20 years of balance sheets for Ionis Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Ionis Pharmaceuticals. Explore the full financial landscape of Ionis Pharmaceuticals stock with our expertly curated balance sheets.
The information provided in this report about Ionis Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.